(Press-News.org) Scientists investigating how one of the greatest shape shifters in the natural world is able to trick predators to avoid being eaten have identified the gene behind the fascinating feat.
The African Swallowtail butterfly, also known as the 'Mocker Swallowtail' or the 'Flying Handkerchief,' can appear to change both colour and shape.
Males of the species fly boldly around the tree tops, their rapid flight making them look like shaking handkerchiefs, however females lurk in the bushes and pretend to be examples of Monarch butterflies that are nasty to eat.
The females mimic different Monarchs in different parts of Africa and how they do this has long been a mystery. In an international collaboration involving scientists from the Natural History Museum, Imperial College London, the University of Cambridge and researchers in Nairobi, Paris and Jena in Germany, The University of Exeter's Professor Richard ffrench-Constant (correct spelling) has helped solve the genetic switch that allows female swallowtails to look like different Monarch butterflies and thus avoid being eaten.
"This mimicry is not just a simple change of colour and pattern", says Prof ffrench-Constant, "but the females also lose their characteristic swallow tails and even fly slowly like Monarch butterflies".
This unique combination of shape-shifting makes the mimicry more convincing for predatory birds and once they learn to avoid one warning pattern, they will then avoid similar looking butterflies.
Dr Martijn Timmermans of Imperial College London, who led the study, said: "The wings of the Mocker Swallowtails have bewildered biologists for almost a century. By pinpointing the switch, we have revealed a unique mechanism. It is really exciting to show that all this diversity is determined by variation in just a single gene."
The genetic switch appears to be the gene called 'engrailed', a gene previously shown to be important in patterning the early embryo of fruit flies. The engrailed gene belongs to a family of genes called transcription factors that switch on networks of genes responsible for all aspects of development.
Previously the engrailed gene has been shown to be important in setting up patterning in developing fruit fly embryos, however, nature seems to have redeployed this gene into much later patterning – the patterning of a butterfly wing. This allows the engrailed gene to function both early in embryo development and then later as a master mimicry switch gene by changing the colour and shape of the butterflies wing.
"We still have a lot to learn" adds ffrench-Constant, "we don't really understand how this gene can control such a wide range of characteristics and how this mimicry is limited only to the female of the species. However, such questions are bound to provide significant challenges for the team in the future."
INFORMATION:
Richard ffrench-Constant is a Professor of Molecular Natural History based at the Centre for Ecology and Conservation at the University of Exeter's Penryn Campus in Cornwall.
'Comparative genomics of the mimicry switch in Papilio dardanus' by Martijn J. T. N. Timmermans, Simon W. Baxter, Rebecca Clark, David G. Heckel, Heiko Vogel, Steve Collins, Alexie Papanicolaou, Iva Fukova, Mathieu Joron, Martin J. Thompson, Chris D. Jiggins,Richard H. Ffrench-Constant and Alfried P. Vogler is published today in the journal Proceedings of the Royal Society B.
Scientists unravel the genetic secrets of nature's master of mimicry
2014-06-11
ELSE PRESS RELEASES FROM THIS DATE:
Infant nutrition and development of type 1 diabetes
2014-06-11
Previous studies have indicated that early exposure to complex foreign proteins, such as cow's milk proteins, increases the risk of type 1 diabetes in predisposed individuals.
"Therefore, In 2002, we embarked on a large-scale study on more than 2100 infants with a family member affected by type 1 diabetes and with genetic disease susceptibility to find an answer to the question whether delaying the exposure to complex foreign proteins will decrease the risk of diabetes", tells Professor Mikael Knip from the University of Helsinki, the leader of the TRIGR Study.
After ...
New guidance on how and when to stop immunosuppressants in lupus patients
2014-06-11
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that, for the majority of lupus patients who are in remission, it is possible to successfully stop immunosuppressant therapy without triggering a flare of their disease.1 Within two years, it was possible to stop the immunosuppressant in about 70% of clinically stable patients. Half were successful within three years, and this proportion remained stable for up to five years.1
Lupus is a chronic inflammatory disease that can affect any organ system, but mainly involves ...
First biomarkers found to predict severe osteoarthritis
2014-06-11
The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) identify a correlation between the presence of biomarkers in the blood, known as micro RNAs (miRNAs), and the development of severe osteoarthritis (OA) of the knee or hip joint. The findings suggest that miRNAs may be used as biomarkers to predict severe OA disease in individuals.2
Preventative measures and early treatments are considered to be the most effective way of managing OA, but to date there has been no way of identifying the disease early on.2
"These ...
New data clarify relationship between diet and disease activity
2014-06-11
Two new studies presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) have helped clarify the relationship between the dietary intake of monounsaturated fatty acids and cholesterol with disease activity in rheumatoid arthritis (RA) and osteoarthritis (OA) respectively.
In the TOMORROW study, daily intake of monounsaturated fatty acids as a component of the Mediterranean diet has been shown to be an independent predictor of remission in patients with RA; monounsaturated fatty acids might therefore be suppressing disease activity1
In another ...
One-third of psoriatic arthritis patients are not receiving optimal dosing of adalimumab
2014-06-11
Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.1 Further data revealed that, in the case of the TNFα inhibitor infliximab, nearly three-quarters of PsA patients were on doses lower than recommended in international guidelines. 2
In the first study, after 28 weeks of treatment one-third of PsA patients were ...
Romosozumab signif increases bone mineral density and bone content compared with teriparatide
2014-06-11
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also compared with the commonly prescribed anabolic agent teriparatide and placebo.1
Romosozumab, administered subcutaneously at monthly intervals over a period of 12 months, resulted in gains in both the trabecular* and cortical† compartments of the spine and hip regions, with important differences ...
Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity
2014-06-11
New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that the newly-approved infliximab biosimilar CT-P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product infliximab (INX).1
CT-P13 is the world's first biosimilar monoclonal antibody to receive a positive opinion from an advanced and developed nations' regulatory body. According to Dr Won Park, Inha University Hospital, Korea, and lead investigator ...
New patient empowerment and educational initiatives unveiled at EULAR 2014
2014-06-11
Five different presentations at the European League Against Rheumatism Annual Congress (EULAR 2014) have introduced new patient empowerment and educational initiatives, which are predicted to bring significant benefits to the many thousands of patients worldwide who suffer from a rheumatic disease.
These initiatives include:
A new model of patient care involving self-monitoring and patient initiated follow-up1
An online learning resource to prepare patients and carers to actively engage in research, guideline development, advocacy and media activities2
A new patient ...
EULAR driving research and innovation in rheumatic and RMDs in Europe
2014-06-11
The European League Against Rheumatism (EULAR) has announced today at its Annual Congress major successes in driving the public agenda for addressing the escalating burden of RMDs in Europe. These advances include:
Recognition for Rheumatic and Musculoskeletal Diseases (RMDs) from major European Commission research initiative, Horizon 2020
'FOREUM', Foundation for Research in Rheumatology, grants research funding for four osteoarthritis projects in its first year.
"It is with great satisfaction that we have seen a progressive dedication of EU research funds for RMDs ...
Tendon stimulation the key to repair in 'tennis elbow'
2014-06-11
New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that ultrasound-guided injections of growth factors-containing platelet-rich plasma (PRP) are no more effective in treating recently developed epicondylitis than injections of saline.1
Lead researcher, Patrick Le Goux of the Hôpitaux Universitaires Paris Ile-de-France Ouest, France, commented, "while PRP injections were shown to have no inherent benefit in the treatment of epicondylitis, what is exciting is that pain scores in both treatment groups decreased significantly ...